{'Year': '2018', 'Month': 'Sep'}
Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.
Outcomes of tailoring statin-type based on solute carrier organic anion transporterfamily member 1B1 ( SLCO1B1)pharmacogenetic toxicity information on patient, provider, and pharmacological outcomes are unknown.